Mechanistic studies on the synergistic cytotoxicity of the nucleoside analogs gemcitabine and clofarabine in multiple myeloma: Relevance of p53 and its clinical implications

Experimental Hematology

Volumn 41, Issue 8, 2013, Pages 719-730

  Valdez, Benigno C ^a   Wang, Guiyun ^a   Murray, David ^b   Nieto, Yago ^a   Li, Yang ^a   Shah, Jatin ^a   Turturro, Francesco ^a   Wang, Michael ^a   Weber, Donna M ^a   Champlin, Richard E ^a   Qazilbash, Muzaffar H ^a   Andersson, Borje S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b CROSS CANCER INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CLOFARABINE; DEOXYCYTIDINE KINASE; GEMCITABINE; HISTONE H2AX; PIFITHRIN ALPHA; PROTEIN P53; RIBOSOME RNA;

ARTICLE; CANCER RESISTANCE; CELL NUCLEUS; CONTROLLED STUDY; CYTOPLASM; DNA DAMAGE; DRUG CYTOTOXICITY; DRUG POTENTIATION; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; MULTIPLE MYELOMA; MYELOMA CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ADENINE NUCLEOTIDES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARABINONUCLEOSIDES; BASE SEQUENCE; CELL LINE, TUMOR; DEOXYCYTIDINE; DNA DAMAGE; DNA PRIMERS; DNA REPAIR; DRUG SYNERGISM; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MULTIPLE MYELOMA; PHOSPHORYLATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84880755309     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2013.04.009     Document Type: Article

References (61)

1. Palumbo A., Cavallo F. Have drug combinations supplanted stem cell transplantation in myeloma?. Blood 2012, 120:4692-4698.
2. Qazilbash M.H., Saliba R.M., Hosing C., et al. Autologous stem cell transplantation is safe and feasible in elderly patients with multiple myeloma. Bone Marrow Transplant 2007, 39:279-283.
3. Brenner H., Gondos A., Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 2008, 111:2521-2526.
4. Efebera Y.A., Qureshi S.R., Cole S.M., et al. Reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed multiple myeloma. Biol Blood Marrow Transplant 2010, 16:1122-1129.
5. Krishnan A., Pasquini M.C., Logan B., et al. Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncol 2011, 12:1195-1203.
6. Bashir Q., Khan H., Orlowski R.Z., et al. Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma. Am J Hematol 2012, 87:272-276.
7. Nishihori T., Alsina M. Advances in the autologous and allogeneic transplantation strategies for multiple myeloma. Cancer Control 2011, 18:258-267.
8. Gojo I., Meisenberg B., Guo C., et al. Autologous stem cell transplantation followed by consolidation chemotherapy for patients with multiple myeloma. Bone Marrow Transplant 2006, 37:65-72.
9. Nieto Y., Thall P., Valdez B., et al. High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies. Biol Blood Marrow Transplant 2012, 18:1677-1686.
10. Kolb E.A., Steinherz P.G. A new multidrug reinduction protocol with topotecan, vinorelbine, thiotepa, dexamethasone, and gemcitabine for relapsed or refractory acute leukemia. Leukemia 2003, 17:1967-1972.
11. Rapoport A.P., Guo C., Badros A., et al. Autologous stem cell transplantation followed by consolidation chemotherapy for relapsed or refractory Hodgkin's lymphoma. Bone Marrow Transplant 2004, 34:883-890.
12. Arai S., Letsinger R., Wong R.M., et al. Phase I/II trial of GN-BVC, a gemcitabine and vinorelbine-containing conditioning regimen for autologous hematopoietic cell transplantation in recurrent and refractory Hodgkin lymphoma. Biol Blood Marrow Transplant 2010, 16:1145-1154.
13. Anderlini P., Saliba R.M., Ledesma C., et al. Gemcitabine, fludarabine and melphalan as a reduced-intensity conditioning regimen for allogeneic stem cell transplant in relapsed and refractory Hodgkin lymphoma: Preliminary results. Leuk Lymphoma 2012, 53:499-502.
14. Kebriaei P., Basset R., Ledesma C., et al. Clofarabine combined with busulfan provides excellent disease control in adult patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2012, 18:1819-1826.
15. Nieto Y., Popat U., Anderlini P., et al. Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: Effect of the specific high-dose chemotherapy regimen on outcome. Biol Blood Marrow Transplant 2013, 19:410-417.
16. Gazitt Y., Shaughnessy P., Rothenberg M.L. A phase II trial with gemcitabine and paclitaxel for the treatment of refractory and relapsed multiple myeloma patients. Oncol Rep 2006, 16:877-884.
17. Andersson B.S., Valdez B.C., de Lima M., et al. Clofarabine ± fludarabine with once daily i.v. busulfan as pre-transplant conditioning therapy for advanced myeloid leukemia and MDS. Biol Blood Marrow Transplant 2011, 17:893-900.
18. Magenau J., Tobai H., Pawarode A., et al. Clofarabine and busulfan conditioning facilitates engraftment and provides significant antitumor activity in nonremission hematologic malignancies. Blood 2011, 118:4258-4264.
19. Srivastava S., Jones D., Wood L.L., et al. A phase I trial of high-dose clofarabine, etoposide, and cyclophosphamide and autologous peripheral blood stem cell transplantation in patients with primary refractory and relapsed and refractory non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2011, 17:987-994.
20. Chevallier P., Labopin M., Buchholz S., et al. Clofarabine-containing conditioning regimen for allo-SCT in AML/ALL patients: a survey from the Acute Leukemia Working Party of EBMT. Eur J Haematol 2012, 89:214-219.
21. Buchholz S., Dammann E., Stadler M., et al. Cytoreductive treatment with clofarabine/ara-C combined with reduced-intensity conditioning and allogeneic stem cell transplantation in patients with high-risk, relapsed, or refractory acute myeloid leukemia and advanced myelodysplastic syndrome. Eur J Haematol 2012, 88:52-60.
22. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983, 65:55-63.
23. Chou T.C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984, 22:27-55.
24. Martin S.J., Reutelingsperger C.P., McGahon A.J., et al. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J Exptl Med 1995, 182:1545-1556.
25. Valdez B.C., Li Y., Murray D., Champlin R.E., Andersson B.S. The synergistic cytotoxicity of clofarabine, fludarabine and busulfan in AML cells involves ATM pathway activation and chromatin remodeling. Biochem Pharmacol 2011, 81:222-232.
26. Valdez B.C., Nieto Y., Murray D., et al. Epigenetic modifiers enhance the synergistic cytotoxicity of combined nucleoside analog-DNA alkylating agents in lymphoma cell lines. Exp Hematol 2012, 40:800-810.
27. Smal C., Vertommen D., Bertrand L., et al. Identification of invivo phosphorylation sites on human deoxycytidine kinase. Role of Ser-74 in the control of enzyme activity. J Biol Chem 2006, 281:4887-4893.
28. Valdez B.C., Murray D., Nieto Y., et al. Synergistic cytotoxicity of the DNA alkylating agent busulfan, nucleoside analogs and suberoylanilide hydroxamic acid in lymphoma cell lines. Leuk Lymphoma 2012, 53:973-981.
29. Rogakou E.P., Pilch D.R., Orr A.H., et al. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 1998, 273:5858-5868.
30. Ziv Y., Bielopolski D., Galanty Y., et al. Chromatin relaxation in response to DNA double-strand breaks is modulated by a novel ATM and KAP-1 dependent pathway. Nat Cell Biol 2006, 8:870-876.
31. Ly J.D., Grubb D.R., Lawen A. The mitochondrial membrane potential (deltapsi(m)) in apoptosis; an update. Apoptosis 2003, 8:115-128.
32. Bernardi P. The permeability transition pore. Control points of a cyclosporin A-sensitive mitochondrial channel involved in cell death. Biochim Biophys Acta 1996, 1275:5-9.
33. Heinemann V., Xu Y.Z., Chubb S., et al. Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2',2'-difluorodeoxycytidine. Mol Pharmacol 1990, 38:567-572.
34. Zhenchuk A., Lotfi K., Juliusson G., Albertioni F. Mechanisms of anti-cancer action and pharmacology of clofarabine. Biochem Pharmacol 2009, 78:1351-1359.
35. Dizin E., Ray H., Suau F., Voeltzel T., Dalla Venezia N. Caspase-dependent BRCA1 cleavage facilitates chemotherapy-induced apoptosis. Apoptosis 2008, 13:237-246.
36. Kato M., Nonaka T., Imajoh-Ohmi S. Cleavage at the carboxyl-terminus of Ku80 during apoptosis in human Jurkat T cells. J Biochem 2005, 137:685-692.
37. Huang Y., Nakada S., Ishiko T., et al. Role for caspase-mediated cleavage of Rad51 in induction of apoptosis by DNA damage. Mol Cell Biol 1999, 19:2986-2997.
38. Johnson C.E., Kornbluth S. Caspase cleavage is not for everyone. Cell 2008, 134:720-721.
39. Bouffard D.Y., Laliberte J., Momparler R.L. Kinetic-studies on 2',2'-difluorodeoxycytidine (gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase. Biochem Pharmacol 1993, 45:1857-1861.
40. Xie C., Plunkett W. Metabolism and actions of 2-chloro-9-(2-deoxy-2-fluorobeta-D-arabinofuranosyl)-adenine in human lymphoblastoid cells. Cancer Res 1995, 55:2847-2852.
41. Amsailale R., Van Den Neste E., Arts A., Starczewska E., Bontemps F., Smal C. Phosphorylation of deoxycytidine kinase on Ser-74: Impact on kinetic properties and nucleoside analog activation in cancer cells. Biochem Pharmacol 2012, 84:43-51.
42. Yang C., Lee M., Hao J., et al. Deoxycytidine kinase regulates the G2/M checkpoint through interaction with cyclin-dependent kinase 1 in response to DNA damage. Nucleic Acids Res 2012, 40:9621-9632.
43. Drexler H.G. The leukemia-lymphoma cell line factsbook 2001, Academic Press, San Diego, CA.
44. Komarov P.G., Komarova E.A., Kondratov R.V., et al. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 1999, 285:1733-1737.
45. Furman P.A., Lam A.M., Murakami E. Nucleoside analog inhibitors of hepatitis C viral replication: Recent advances, challenges and trends. Future Med Chem 2009, 1:1429-1452.
46. Huang P., Sandoval A., Van Den Neste E., Keating M.J., Plunkett W. Inhibition of RNA transcription: a biochemical mechanism of action against chronic lymphocytic leukemia cells by fludarabine. Leukemia 2000, 14:1405-1413.
47. Chen L.S., Plunkett W., Gandhi V. Polyadenylation inhibition by the triphosphates of deoxyadenosine analogues. Leuk Res 2008, 32:1573-1581.
48. Learned R.M., Learned T.K., Haltiner M.M., Tjian R. Human rRNA transcription is modulated by the coordinate binding of two factors to an upstream control element. Cell 1986, 45:847-857.
49. Valdez B.C., Perlaky L., Henning D., Saijo Y., Chan P.K., Busch H. Identification of the nuclear and nucleolar localization signals of the protein p120. Interaction with translocation protein B23. J Biol Chem 1994, 269:23776-23783.
50. Valdez B.C., Henning D., So R.B., Dixon J., Dixon M.J. The Treacher Collins syndrome (TCOF1) gene product is involved in ribosomal DNA gene transcription by interacting with upstream binding factor. Proc Natl Acad Sci U S A 2004, 101:10709-10714.
51. Grummt I. Regulation of mammalian ribosomal gene transcription by RNA polymerase I. Prog Nucleic Acid Res Mol Biol 1999, 62:109-154.
52. Parker W.B., Shaddix S.C., Chang C.H., et al. Effects of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5'-triphosphate. Cancer Res 1991, 51:2386-2394.
53. Ewald B., Sampath D., Plunkett W. Nucleoside analogs: molecular mechanisms signaling cell death. Oncogene 2008, 27:6522-6537.
54. Hazra S., Szewczak A., Ort S., Konrad M., Lavie A. Post-translational phosphorylation of serine 74 of human deoxycytidine kinase favors the enzyme adopting the open conformation making it competent for nucleoside binding and release. Biochemistry 2011, 50:2870-2880.
55. Ohmine K., Kawaguchi K., Ohtsuki S., et al. Attenuation of phosphorylation by deoxycytidine kinase is key to acquired gemcitabine resistance in a pancreatic cancer cell line: targeted proteomic and metabolomic analyses in PK9 cells. Pharm Res 2012, 29:2006-2016.
56. Saiki Y., Yoshino Y., Fujimura H., et al. DCK is frequently inactivated in acquired gemcitabine-resistant human cancer cells. Biochem Biophys Res Commun 2012, 421:98-104.
57. Liu X., Kim C.N., Yang J., Jemmerson R., Wang X. Induction of apoptotic program in cell-free extracts: Requirement for dATP and cytochrome c. Cell 1996, 86:147-157.
58. Susin S.A., Lorenzo H.K., Zamzami N., et al. Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 1999, 397:441-446.
59. Eriksson S., Kierdaszuk B., Munchpetersen B., Oberg B., Johansson N.G. Comparison of the substrate specificities of human thymidine kinase-1and kinase-2 and deoxycytidine kinase toward antiviral and cytostatic nucleoside analogs. Biochem Biophys Res Comm 1991, 176:586-592.
60. Genini D., Adachi S., Chao Q., et al. Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria. Blood 2000, 96:3537-3543.
61. Boulon S., Westman B.J., Hutten S., Boisvert F.M., Lamond A.I. The nucleolus under stress. Mol Cell 2010, 40:216-227.